E. Fonsatti

A. Leonardi, M. Maio, C. Pucillo, 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Vaccination of Stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells

M. Colombo, M. Maio, G. Parmiani, 2002, Cancer Immunology, Immunotherapy.

Functional Up-regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-aza-2′-deoxycytidine in Cutaneous Melanoma: Immunotherapeutic Implications

F. Marincola, M. Maio, M. Guidoboni, 2007, Clinical Cancer Research.

Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?

M. Maio, E. Fonsatti, A. D. Di Giacomo, 2004, Journal of Translational Medicine.

A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients.

M. Maio, D. Giannarelli, R. Danielli, 2014 .

Overexpression of protectin (CD59) down‐modulates the susceptibility of human melanoma cells to homologous complement

M. Colombo, M. Maio, G. Romano, 2000, Journal of cellular physiology.

Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity.

M. Maio, A. Visintin, F. Colizzi, 1997, The Journal of clinical investigation.

Expression of protectin (CD59) in human melanoma and its functional role in cell‐ and complement‐mediated cytotoxicity

A. Cattelan, A. Carbone, A. Gloghini, 1995, International journal of cancer.

The Italian Network for Tumor Biotherapy (NIBIT). Sharing Visions, Goals and Efforts at European Level

M. Maio, G. Parmiani, E. Fonsatti, 2008, Tumori.

The Italian Network for Tumor Biotherapy (NIBIT): Getting together to push the field forward

P. Ascierto, M. Colombo, P. Queirolo, 2008, Journal of Translational Medicine.

Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study

M. Maio, G. Parmiani, D. Giannarelli, 2016, Oncoimmunology.

ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies.

M. Maio, R. Danielli, E. Fonsatti, 2016, Methods in molecular biology.

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.

P. Ascierto, A. Testori, E. Simeone, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Methylation‐regulated expression of cancer testis antigens in primary effusion lymphoma: Immunotherapeutic implications

M. Maio, L. Sigalotti, F. Colizzi, 2005, Journal of cellular physiology.

Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: Immunotherapeutic implications

M. Maio, P. Natali, E. Fratta, 2006, Journal of Cellular Physiology.

Endoglin (CD105): a target for anti-angiogenetic cancer therapy.

M. Maio, E. Fonsatti, M. Altomonte, 2003, Current drug targets.

Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer

M. Maio, E. Fonsatti, 2004, Journal of Translational Medicine.

Biology and clinical applications of CD40 in cancer treatment.

P. Hersey, M. Maio, E. Fonsatti, 2010, Seminars in oncology.

Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review).

M. Maio, A. Visintin, L. Sigalotti, 1998, International journal of oncology.

Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies.

M. Maio, L. Sigalotti, E. Fonsatti, 2003, Current cancer drug targets.

Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.

A. Cattelan, M. Maio, P. Natali, 1996, Laboratory investigation; a journal of technical methods and pathology.

Recombinant transmembrane CD59 (CD59‐TM) confers complement resistance to GPI‐anchored protein defective melanoma cells *

M. Maio, L. Sigalotti, F. Colizzi, 2002 .

Tumour-derived interleukin 1alpha (IL-1alpha) up-regulates the release of soluble intercellular adhesion molecule-1 (sICAM-1) by endothelial cells.

M. Maio, P. Natali, E. Fonsatti, 1997, British Journal of Cancer.

Emerging role of protectin (CD59) in humoral immunotherapy of solid malignancies.

M. Maio, P. Natali, L. Sigalotti, 2000, La Clinica terapeutica.

Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond

M. Maio, R. Danielli, E. Fonsatti, 2012, Annals of the New York Academy of Sciences.

Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications

M. Maio, E. Fratta, L. Sigalotti, 2007, Journal of cellular physiology.

Epigenetically regulated tumor-associated antigens in melanoma

M. Maio, E. Fratta, L. Sigalotti, 2009 .

Epigenetic remodelling of DNA in cancer.

M. Maio, M. Guidoboni, E. Fonsatti, 2007, Histology and histopathology.

Review Epigenetic remodelling of DNA in cancer

M. Maio, M. Guidoboni, E. Fonsatti, 2007 .

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.

P. Ascierto, A. Testori, E. Simeone, 2012, The Lancet. Oncology.

The Italian Network for Tumor Biotherapy (NIBIT): past, present and future goals

M. Maio, E. Fonsatti, 2014 .

Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignangies.

M. Maio, E. Fonsatti, M. Altomonte, 2001, Frontiers in bioscience : a journal and virtual library.

Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model.

M. Maio, M. Snellman, P. Natali, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications

M. Maio, E. Fratta, L. Sigalotti, 2012, British Journal of Cancer.

In vitro analysis of the melanoma/endothelium interaction increasing the release of soluble intercellular adhesion molecule 1 by endothelial cells

M. Colombo, M. Maio, L. Sigalotti, 1999, Cancer Immunology, Immunotherapy.

Immunologic correlates in the course of treatment with immunomodulating antibodies.

L. Zitvogel, B. Weide, E. Fonsatti, 2015, Seminars in oncology.

The Coincidence of Chromosome 15 Aberrations and β2-Microglobulin Gene Mutations Is Causative for the Total Loss of Human Leukocyte Antigen Class I Expression in Melanoma

D. Schadendorf, M. Maio, A. Cerwenka, 2006, Clinical Cancer Research.

Epigenetic immunomodulation of hematopoietic malignancies.

M. Maio, L. Sigalotti, E. Fonsatti, 2005, Seminars in oncology.

Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma and peritoneal fluid from ovarian cancer patients

M. Maio, E. Fonsatti, Antonia Anna Anzalone, 2005 .

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme

M. Maio, C. Miracco, D. Giannarelli, 2013, Cancer Immunology, Immunotherapy.

CD40 Expression by Human Melanocytic Lesions and Melanoma Cell Lines and Direct CD40 Targeting With the Therapeutic Anti-CD40 Antibody CP-870,893

A. Ribas, W. Tap, M. Maio, 2010, Journal of immunotherapy.

Targeting of HLA‐DR molecules transduces agonistic functional signals in cutaneous melanoma

A. Leonardi, M. Maio, C. Pucillo, 2004, Journal of cellular physiology.

Endoglin: An accessory component of the TGF‐β‐binding receptor‐complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies

M. Maio, P. Natali, L. Sigalotti, 2001, Journal of cellular physiology.

Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments?

M. Maio, M. Mazzei, C. Miracco, 2007, Journal of experimental & clinical cancer research : CR.

Endoglin (CD105): A Strong Candidate for Immunologic Targeting of Tumor Neovasculature in Human Malignancies

M. Maio, E. Fonsatti, 2008 .

Is it the primetime for endoglin (CD105) in the clinical setting?

M. Maio, E. Fonsatti, M. Altomonte, 2006, Cardiovascular research.

Is it the primetime for endoglin ( CD 105 ) in the clinical setting ?

M. Maio, E. Fonsatti, M. Altomonte, 2006 .

Differential levels of soluble endoglin (CD105) in myeloid malignancies

M. Maio, A. Alonci, C. Musolino, 2003, Journal of cellular physiology.

A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial.

P. Ascierto, P. Queirolo, M. Mandalà, 2015 .

A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial.

P. Ascierto, A. Testori, P. Queirolo, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Melanoma and other skin tumors

Y. S. Kim, Su Jin Lee, J. Utikal, 2012 .

Abstract 680:In vivoimmunomodulatory activity of SGI-110, a second generation hypomethylating agent, in hematologic malignancies.

M. Maio, E. Fratta, L. Sigalotti, 2013 .

Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells.

M. Maio, L. Sigalotti, F. Colizzi, 2002, Journal of cellular physiology.

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.

M. Maio, L. Mutti, D. Giannarelli, 2013, The Lancet. Oncology.

Intratumor Heterogeneity of Cancer/Testis Antigens Expression in Human Cutaneous Melanoma Is Methylation-Regulated and Functionally Reverted by 5-Aza-2′-deoxycytidine

M. Maio, R. Danielli, C. Traversari, 2004, Cancer Research.